Pamela J Burgess

Array ( [id] => 16627522 [patent_doc_number] => 20210046175 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => HIV VACCINES COMPRISING ONE OR MORE POPULATION EPISENSUS ANTIGENS [patent_app_type] => utility [patent_app_number] => 17/008335 [patent_app_country] => US [patent_app_date] => 2020-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19961 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17008335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16627521 [patent_doc_number] => 20210046174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => HIV VACCINES COMPRISING ONE OR MORE POPULATION EPISENSUS ANTIGENS [patent_app_type] => utility [patent_app_number] => 17/008289 [patent_app_country] => US [patent_app_date] => 2020-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19967 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17008289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16673457 [patent_doc_number] => 20210062220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => METHODS AND CONSTRUCTS FOR PRODUCTION OF LENTIVIRAL VECTOR [patent_app_type] => utility [patent_app_number] => 17/001114 [patent_app_country] => US [patent_app_date] => 2020-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11114 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17001114 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18341281 [patent_doc_number] => 11638750 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-02 [patent_title] => Methods for generating a Zikv immune response utilizing a recombinant modified vaccina Ankara vector encoding the NS1 protein [patent_app_type] => utility [patent_app_number] => 17/000768 [patent_app_country] => US [patent_app_date] => 2020-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 17515 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17000768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657418 [patent_doc_number] => 20210054054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => ENGINEERING PH-DEPENDENT ANTIGEN BINDING ACTIVITY INTO ANTI-HIV ANTIBODIES WITH IMPROVED PHARMACOKINETICS [patent_app_type] => utility [patent_app_number] => 16/997547 [patent_app_country] => US [patent_app_date] => 2020-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7142 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16997547 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17443760 [patent_doc_number] => 20220064265 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => Episomal Expression of Potent Immunoglobulins Derived from Human Blood or Convalescent Plasma to Enable Short term Vaccination / Immunization to COVID, COVID-19 and Mutants and Other Pandemic and non-Pandemic Viruses designed from Rapid FDA approval. [patent_app_type] => utility [patent_app_number] => 16/995829 [patent_app_country] => US [patent_app_date] => 2020-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17465 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 435 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16995829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17076020 [patent_doc_number] => 11112412 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-09-07 [patent_title] => SARS-CoV-2 surrogate virus neutralization assay test kit [patent_app_type] => utility [patent_app_number] => 16/939405 [patent_app_country] => US [patent_app_date] => 2020-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 30 [patent_no_of_words] => 20380 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16939405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452618 [patent_doc_number] => 20200362044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => Methods of Treating Cytokine Storm Infections, Including COVID-19, By Inhibiting CCR5/CCL5 (RANTES) Interaction, and Compositions for Practicing the Same [patent_app_type] => utility [patent_app_number] => 16/932636 [patent_app_country] => US [patent_app_date] => 2020-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11037 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16932636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16391049 [patent_doc_number] => 20200331990 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => MOBILIZING HIV-INFECTED CELLS FROM LYMPHATIC RESERVOIRS [patent_app_type] => utility [patent_app_number] => 16/921682 [patent_app_country] => US [patent_app_date] => 2020-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8082 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16921682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16359416 [patent_doc_number] => 20200316167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4 [patent_app_type] => utility [patent_app_number] => 16/912199 [patent_app_country] => US [patent_app_date] => 2020-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16912199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16466806 [patent_doc_number] => 20200368343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => ZIKA VIRUS MRNA VACCINES [patent_app_type] => utility [patent_app_number] => 16/897859 [patent_app_country] => US [patent_app_date] => 2020-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70306 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16897859 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16329890 [patent_doc_number] => 20200300856 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => RECOMBINANT BACULOVIRUSES AND THEIR USES IN DETECTING ARTHROPOD-BORNE VIRUS [patent_app_type] => utility [patent_app_number] => 16/892289 [patent_app_country] => US [patent_app_date] => 2020-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5527 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16892289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16483975 [patent_doc_number] => 20200377576 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => HIV-1 SPECIFIC IMMUNOGEN COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/887710 [patent_app_country] => US [patent_app_date] => 2020-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17749 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16887710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16483975 [patent_doc_number] => 20200377576 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => HIV-1 SPECIFIC IMMUNOGEN COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/887710 [patent_app_country] => US [patent_app_date] => 2020-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17749 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16887710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17095454 [patent_doc_number] => 20210283245 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => Anti COVID-19 Therapies targeting nucleocapsid and spike proteins [patent_app_type] => utility [patent_app_number] => 16/883263 [patent_app_country] => US [patent_app_date] => 2020-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16883263 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18574307 [patent_doc_number] => 11730813 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-22 [patent_title] => Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof [patent_app_type] => utility [patent_app_number] => 16/882354 [patent_app_country] => US [patent_app_date] => 2020-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 33 [patent_no_of_words] => 46671 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16882354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18558752 [patent_doc_number] => 11723977 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-15 [patent_title] => Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof [patent_app_type] => utility [patent_app_number] => 16/882359 [patent_app_country] => US [patent_app_date] => 2020-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 33 [patent_no_of_words] => 46699 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16882359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17118780 [patent_doc_number] => 11129890 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-09-28 [patent_title] => Non-integrating [patent_app_type] => utility [patent_app_number] => 16/877839 [patent_app_country] => US [patent_app_date] => 2020-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 15 [patent_no_of_words] => 26012 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16877839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16466810 [patent_doc_number] => 20200368347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH GP120 V3 GLYCAN-DIRECTED ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/877292 [patent_app_country] => US [patent_app_date] => 2020-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33442 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16877292 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18233210 [patent_doc_number] => 11597759 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-07 [patent_title] => Multispecific antibodies that target HIV GP120 and CD3 [patent_app_type] => utility [patent_app_number] => 16/867924 [patent_app_country] => US [patent_app_date] => 2020-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56224 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 183 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867924 [rel_patent_id] =>[rel_patent_doc_number] =>)